These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
474 related items for PubMed ID: 9815797
1. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Geiger T, Müller M, Monia BP, Fabbro D. Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797 [Abstract] [Full Text] [Related]
3. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models. Mewani RR, Tang W, Rahman A, Dritschilo A, Ahmad I, Kasid UN, Gokhale PC. Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340 [Abstract] [Full Text] [Related]
12. The hollow fiber assay: continued characterization with novel approaches. Hall LA, Krauthauser CM, Wexler RS, Hollingshead MG, Slee AM, Kerr JS. Anticancer Res; 2000 Sep 01; 20(2A):903-11. PubMed ID: 10810375 [Abstract] [Full Text] [Related]
13. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB. Clin Cancer Res; 2004 Nov 15; 10(22):7662-70. PubMed ID: 15569999 [Abstract] [Full Text] [Related]
14. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, Varki NM, Appelt K. Clin Cancer Res; 1999 Jul 15; 5(7):1905-17. PubMed ID: 10430098 [Abstract] [Full Text] [Related]
15. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization. Schiller JH, Bittner G. Clin Cancer Res; 1999 Dec 15; 5(12):4287-94. PubMed ID: 10632372 [Abstract] [Full Text] [Related]
18. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J, Young A. Cancer Res; 2003 Jun 01; 63(11):2802-11. PubMed ID: 12782585 [Abstract] [Full Text] [Related]